Literature DB >> 22440998

Pheochromocytoma with histologic transformation to composite type, complicated by watery diarrhea, hypokalemia, and achlorhydria syndrome.

Yuki Kikuchi1, Ryuichi Wada, Satoru Sakihara, Toshihiro Suda, Soroku Yagihashi.   

Abstract

OBJECTIVE: To describe the rare occurrence of histologic transformation of a pheochromocytoma to a composite type of tumor during a long-term follow-up, which was complicated by watery diarrhea, hypokalemia, and achlorhydria syndrome.
METHODS: We report the case of a 12-year-old girl who presented with headache, hypertension, and elevated catecholamine levels in the blood and urine. A tumor was found in the right adrenal gland and resected. When she was 15 years of age, multiple metastatic nodules were found in the lung and liver. Intensive chemotherapy was ineffective, and she underwent follow-up with conservative therapy. At 25 years of age, she complained of diarrhea. Laboratory studies revealed hypokalemia and an increase in the level of serum vasoactive intestinal polypeptide (VIP). A year later, she died of extensive metastatic disease. The primary and recurrent tumors at autopsy were histologically examined.
RESULTS: The primary tumor was pure pheochromocytoma, and the tumors at autopsy were a composite type of pheochromocytoma and ganglioneuroma. Only a few VIP-positive cells were found in the primary tumor, whereas both pheochromocytoma and ganglioneuroma cells of composite tumors were frequently positive for VIP.
CONCLUSION: Our case showed histologic transformation from pheochromocytoma to a composite type of tumor during a 14-year clinical course, which was associated with additional hormone production and a change in symptoms. Careful attention should be paid to the alteration of endocrine symptoms and hormone levels during prolonged follow-up of pheochromocytoma in young patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22440998     DOI: 10.4158/EP11370.CR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Composite pheochromocytoma masquerading as solid-pseudopapillary neoplasm of pancreas.

Authors:  Geetanjali Gupta; Ravindra Kumar Saran; Satyajit Godhi; Siddharth Srivastava; Sundeep Singh Saluja; Pramod Kumar Mishra
Journal:  World J Clin Cases       Date:  2015-05-16       Impact factor: 1.337

Review 2.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

3.  Diverse proportion in composite pheochromocytoma-ganglioneuroma may induce varied clinical symptom: comparison of two cases.

Authors:  Bu-Yi Zhang; Mingfei Zhao; Baizhou Li; Jian-Min Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Composite pheochromocytoma of the adrenal gland: a case series.

Authors:  Yohei Shida; Tsukasa Igawa; Kuniko Abe; Tomoaki Hakariya; Kousuke Takehara; Toru Onita; Hideki Sakai
Journal:  BMC Res Notes       Date:  2015-06-24

5.  Expression of Extracellular Signal-regulated Kinase 5 and Ankyrin Repeat Domain 1 in Composite Pheochromocytoma and Ganglioneuroblastoma Detected Incidentally in the Adult Adrenal Gland.

Authors:  Shinta Suenaga; Osamu Ichiyanagi; Hiromi Ito; Sei Naito; Tomoyuki Kato; Akira Nagaoka; Tomoya Kato; Mitsunori Yamakawa; Yutaro Obara; Norihiko Tsuchiya
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

6.  Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature.

Authors:  Shelby K Yee; John H Meyer; Linda L Wong
Journal:  AACE Clin Case Rep       Date:  2022-04-01

7.  Case Report: Composite pheochromocytoma with ganglioneuroma component: A report of three cases.

Authors:  Paula B Araujo; Mirna S Carvallo; Ana P Vidal; João B Nascimento; Julia M Wo; Erika O Naliato; Silvio H Cunha Neto; Flavia L Conceição; Rosita Fontes; Vinicius V de Lima; Denise P Carvalho; Paula Soares; Jorge Lima; Delmar M Lourenço; Alice Helena D Violante
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-14       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.